ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Epithelial Carcinoma

Triple Negative Breast Cancer trials near London, England, GBR:

Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer (DIAMOND)

Durvalumab is more effective than Dato-DXd alone in treating PDL1-negative advanced or metastatic triple negative breast...

Begins enrollment in 2 months
Triple Negative Breast Cancer
Drug: Datopotamab Deruxtecan (Dato-DXd)
Drug: Durvalumab

Phase 2

Queen Mary University of London

London, United Kingdom

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA)

of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Capivasertib
Drug: Trastuzumab deruxtecan

Phase 1, Phase 2

AstraZeneca
AstraZeneca

London, United Kingdom and 31 other locations

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

hormone-receptor (HR) positive and HER2 negative advanced breast cancer, the most common subtype of breast cancer...

Enrolling
Locally Advanced Breast Cancer
HER2-positive Breast Cancer
Drug: Avelumab
Drug: Palbociclib

Phase 1

Royal Marsden NHS Foundation Trust

London, United Kingdom and 7 other locations

Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (ROLo)

The purpose of this study is to find out how effective the combination of crizotinib and fulvestrant is in shrinking lobular breast cancer...

Active, not recruiting
Gastric Cancer
Lobular Breast Carcinoma
Drug: Crizotinib Oral Capsule [Xalkori]
Drug: Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]

Phase 2

Royal Marsden NHS Foundation Trust

London, United Kingdom and 4 other locations

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer

PHOENIX is a window of opportunity (WOP), open-label, multi-centre, phase IIa trial comprising multiple non-comparative treatment cohorts with patien...

Enrolling
Breast Neoplasm
Drug: AZD6738
Drug: Durvalumab

Phase 2

Institute of Cancer Research, United Kingdom

London, United Kingdom and 8 other locations

Locations recently updated

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen rec...

Begins enrollment in 2 months
Breast Neoplasms
Drug: Paclitaxel
Drug: Iza-bren

Phase 2, Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

London, London, City Of, United Kingdom and 217 other locations

Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC (BARBICAN)

non-metastatic, high-risk (node positive and/or tumour size ≥ 2cm), triple negative breast cancer. The study aims...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Doxorubicin
Drug: Ipatasertib

Phase 2

Queen Mary University of London

London, United Kingdom

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST)

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...

Active, not recruiting
Neoplasms, Breast
Drug: Placebo
Drug: Niraparib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

London, United Kingdom and 199 other locations

Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer (PARTNER)

This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement ...

Enrolling
Breast Cancer
Drug: Paclitaxel and Carboplatin
Drug: Olaparib

Phase 2, Phase 3

NHS Foundation Trust
NHS Foundation Trust

London, United Kingdom and 29 other locations

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple...

Enrolling
Locally Advanced Breast Cancer
Metastatic Triple Negative Breast Cancers
Drug: BNT327 Equivalent Q3W Dose
Drug: BNT327 Dose Level 1 (DL2)

Phase 2

BioNTech
BioNTech

London, United Kingdom and 66 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems